The diagnosis of chronic inducible urticarias

  • Authors: Borzova EY.1,2
  • Affiliations:
    1. Federal State Budgetary Educational Institution of Further Professional Education Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
    2. Pirogov Russian National Research Medical University of the Russian Ministry of Health
  • Issue: Vol 16, No 2 (2019)
  • Pages: 5-13
  • Section: Articles
  • URL: https://rusalljournal.ru/raj/article/view/1191
  • DOI: https://doi.org/10.36691/RJA1191
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Chronic inducible urticarias are characterized by the risks of systemic reactions and a significant impairment of patient’s quality of life. The diagnosis of chronic inducible urticarias relies on the patient’s history and the challenge tests. A treatment algorithm for the management of chronic inducible urticarias includes nonsedating antihistamines as a first-line treatment. The international guidelines for the management of chronic inducible urticarias recommend updosing of nonsedating antihistamines up to four fold if standard doses are not effective. The meta-analysis suggests the efficacy of omalizumab in chronic inducible urticarias. In the prospect, the novel options of biological therapy for chronic inducible urticarias are expected.

Restricted Access

E Yu Borzova

Federal State Budgetary Educational Institution of Further Professional Education Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation; Pirogov Russian National Research Medical University of the Russian Ministry of Health

Email: eborzova@gmail.com
Department of allergology and immunology; Department of Clinical Genetics, Research and Clinical Institute of Pediatrics n. a. Y.E. Veltischev

  1. Федеральные клинические рекомендации по лечению крапивницы Российской Ассоциации Аллергологов и Иммунологов. M., 2015
  2. Maurer M, Hawro T, Krause K, Magerl M, Metz M, Siebenhaar F et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019. doi: 10.1111/all.13878.
  3. Magerl M, Altrichter S, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI/ GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802. DOI: 10.1111/ all.12884.
  4. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Viera Dos Santos R et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol. 2007;32(3):241-245. doi: 10.1111/j.1365-2230.2007.02376.
  5. Trevisonno J, Balram B, Netchiporouk E, Ben-Shoshan M. Physical urticaria: review on classification, triggers and management with special focus on prevalence including a meta-analysis. Postgrad Med. 2015; 127(6):565-570. doi: 10.1080/00325481.
  6. Grabbe J. Pathomechanisms in physical urticaria. J Investing Dermatol Symp Proc. 2001;6(2):135-13. doi: 10.1046/j.0022-202x.2001.00025.x.
  7. Kojima M, Horiko T, Nakamura Y, Aoki T. Solar urticaria. The relationship of photoallergen and action spectrum. Arch Dermatol. 1986;122(5):550-555.
  8. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol. 1988;90(2):213-217.
  9. Zuberbier T, Schwarz S, Hartmann K, Pfrommer C, Czarnetzki BM. Histamine releasability of basophils and skin mast cells in chronic urticaria. Allergy. 1996;51(1):24-28.
  10. Morioke S, Takahagi S, Iwamoto K, Shindo H, Mihara S, Kameyoshi Y, Hide M. Pressure challenge test and histo-pathological inspections for 17 Japanese cases with clinically diagnosed delayed pressure urticaria. Arch Dermatol Res. 2010;302(8):613-617. doi: 10.1007/s00403-010-1053-4.
  11. Bito T, Sawada Yu, Tokura Y. Pathogenesis of cholinergic urticaria in relation to sweating. Allergology International. 2012;61:539-544. doi: 10.2332/allergolint.12-RAI-0485.
  12. Takahagi S, Tanaka A, Hide M. Sweat allergy. Allergol Int. 2018;67(4):435-441. doi: 10.1016/j.alit.2018.07.002.
  13. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P et al. Cold urticaria, immunodeficiency and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012;366(4):330-8. doi: 10.1056/NEJMoa1102140.
  14. Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM et al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374(7):656-663. doi: 10.1056/NEJMoa1500611.
  15. Soter NA, Wasserman SI. Physical urticaria/angioedema: an experimental model of mast cell activation in humans. J Allergy Clin Immunol. 1980;66(5): 358-365.
  16. Andersson T, Wardell K, Anderson C. Human in vivo cutaneous microdialysis: estimation of histamine release in cold urticaria. Acta Derm Venereol. 1995;75(5):343-347. DOI: 10.234/0001555575343347.
  17. Sanchez J, Amaya E, Acevedo A, Celis A, Caraballo D, Cardona R. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors. J Allergy Clin Immunol Pract. 2017;5(2):464-470. DOI: 10.1016/j. jaip.2016.09.029.
  18. Grimm V, Mempel M, Ring J, Abeck D. Congenital symptomatic dermographism as the first symptom of mastocytosis. Br J Dermatol. 2000;143(5):1109.
  19. Martinez-Escala M, Curto-Barredo L, Carnero L, Pujol RM, Gimenez-Arnau AM. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol. 2015;95(3):278-282. doi: 10.2340/00015555-1918.
  20. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Derm. 1993;29:954-958.
  21. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Gren-delmeier P, Bircher A, Simon D. Urticaria and angioedema: an update on classification and pathogenesis. Clinical Reviews Allergy Immunol. 2018;54(1):88-101. doi: 10.1007/s12016- 017-8628-1.
  22. Komarow HD, Arceo S, Young M, Nelson C, Metcalfe DD. Dissociation between history and challenge in patients with physical urticaria. J Allergy Clin Immunol Pract. 2014;2(6):786-790. doi: 10.1016/j.jaip.2014.07.008.
  23. Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK et al. Definition, aims and implementation of GA2LEN Urticaria Centers of Reference and Excellence. Allergy. 2016;71:1210-1218. doi: 10.1111/all.12901.
  24. Magerl MT, Abajian M, Krause K, Altrichter S et al. An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. J Eur Acad Dermatol Venereol. 2014;29(10):2043-2045. doi: 10.1111/jdv.12739.
  25. Krause K, Grattan CE, Bindslev-Jensen C, Gattorno M, Kallinich T, de Koning HD et al. How not to miss auto-inflammatory diseases masquerading as urticaria. Allergy. 2012;67(12):1465-1474. doi: 10.1111/all.12030.
  26. Goetze S, Elsner P. Solar urticaria. J Dtsch Dermatol Ges. 2015;13(12):1250-1253. doi: 10.1111/ddg.12809.
  27. Montgomery SL. Cholinergic urticaria and exercise-induced anaphylaxis. Curr Sports Med Rep. 2015;14(1):61-63. doi: 10.1249/JSR.0000000000000111.
  28. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with stan-dard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672-679. doi: 10.1016/j.jaa-ci.2008.12.008.
  29. Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol. 2016;96(1):56-59. doi: 10.2340/00015555-2150.
  30. Dressler C, Werner RN, Eisert L, Zuberbier T, Nast A, Maurer M. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726-1734. doi: 10.1016/j.jaci.2018.01.031.
  31. Kocaturk E, Can PK, Akbas PE, Copur M, Depirmentepe EN, Kizitac K, Singer R. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci. 2017;87(1):60-69. DOI: 10.1016/j. jdermsci.2017.02.283.
  32. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638-649. DOI: 10.1016/j. jaci.2017.06.032.
  33. Sanchez Borges M, Gonzalez-Aveledo L, Caballero-Fonseca F, Capriles-Hulett A. Review of physical urticarias and testing methods. Curr Allergy Asthma Rep. 2017;17(8):51. doi: 10.1007/s11882-017-0722-1.
  34. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119-1130. doi: 10.1016/j.jaip.2018.03.007.
  35. Bergmann KC, Altrichter S, Maurer M. Benefit of bendral-izumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019. doi: 10.1111/jdv.15720.

Views

Abstract - 41

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies